Grifols/$GRFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Ticker
$GRFS
Sector
Primary listing
Employees
25,258
Headquarters
Website
Grifols Metrics
BasicAdvanced
$6.7bn
12.13
$0.69
1.19
$0.14
1.69%
Price and volume
Market cap
$6.7bn
Beta
1.19
52-week high
$11.14
52-week low
$7.09
Average daily volume
703k
Dividend rate
$0.14
Financial strength
Current ratio
2.513
Quick ratio
0.839
Long term debt to equity
119.571
Total debt to equity
126.832
Dividend payout ratio (TTM)
31.84%
Interest coverage (TTM)
2.42%
Profitability
EBITDA (TTM)
1,994.756
Gross margin (TTM)
38.80%
Net profit margin (TTM)
5.34%
Operating margin (TTM)
18.54%
Effective tax rate (TTM)
18.70%
Revenue per employee (TTM)
$352,590
Management effectiveness
Return on assets (TTM)
4.24%
Return on equity (TTM)
6.17%
Valuation
Price to earnings (TTM)
12.128
Price to revenue (TTM)
0.647
Price to book
1.08
Price to tangible book (TTM)
-2.21
Price to free cash flow (TTM)
7.804
Free cash flow yield (TTM)
12.81%
Free cash flow per share (TTM)
1.078
Dividend yield (TTM)
1.69%
Growth
Revenue change (TTM)
4.33%
Earnings per share change (TTM)
156.52%
3-year revenue growth (CAGR)
7.46%
10-year revenue growth (CAGR)
6.70%
3-year earnings per share growth (CAGR)
29.77%
10-year earnings per share growth (CAGR)
-2.73%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $6.7B as of May 07, 2026.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 12.13 as of May 07, 2026.
Does Grifols stock pay dividends?
Yes, the Grifols (GRFS) stock pays dividends to shareholders. As of May 07, 2026, the dividend rate is $0.14238 and the yield is 1.69%. Grifols has a payout ratio of 31.84% on a trailing twelve-month basis.
When is the next Grifols dividend payment date?
The next Grifols (GRFS) dividend payment date is unconfirmed.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.